We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

8 hedge funds and large institutions have $287K invested in Viridian Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

248% more capital inflows, than outflows

Capital inflows: $108K | Capital outflows: $31K

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

6.34% less ownership

Funds ownership: 6.34% → 0% (-6.3%)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$56.2K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$25.1K
3
Prelude Capital Management
Prelude Capital Management
New York
+$17.4K
4
Deutsche Bank
Deutsche Bank
Germany
+$7.42K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.57K

Top Sellers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
-$25K
2
Citadel Advisors
Citadel Advisors
Florida
-$5K
3
UBS Group
UBS Group
Switzerland
-$1K

VRDN Hedge Fund Activity: Q4 2016 in Review

8 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2016, worth a combined $287K — down 16% from $341K a quarter earlier.

Fund positioning in VRDN was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $56.2K. The largest seller was Perkins Capital Management, exiting entirely with an estimated $25K sold.

  • 8 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $287K of Viridian Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
  • 3 funds opened new Viridian Therapeutics positions in Q4 2016 and 3 closed out, a net change of 0 holders.
  • The largest Viridian Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $56.2K added.
  • The largest Viridian Therapeutics seller in Q4 2016 was Perkins Capital Management, an estimated $25K sold.

Based on aggregated 13F filings for Q4 2016.